CONDITION

Immune-Mediated Polyarthritis

Why this matters now

Immune-mediated polyarthritis can develop at any age, though different types may have age predispositions. Some forms appear more common in young to middle-aged dogs. Certain breeds, including German Shepherds, Retrievers, and Spaniels, may have increased susceptibility. The condition often develops over days to weeks, though onset can sometimes be more acute.

The condition typically causes joint pain and stiffness that may shift between joints or affect multiple joints simultaneously. Early signs can be subtle, with dogs appearing stiff or reluctant to exercise without obvious lameness. As inflammation persists, joint swelling may become apparent. Without treatment, ongoing immune attack can damage joint structures. The course often fluctuates, with periods of worsening and improvement. Some dogs also show systemic signs such as fever and lethargy.

Signals & patterns

Early signals

Generalised stiffness, especially after rest

Difficulty rising and stiff movement that may improve with gentle activity but differs from typical age-related stiffness.

Reluctance to walk or exercise

Decreased enthusiasm for activities, though no single limb may appear obviously lame.

Shifting leg lameness

Lameness that seems to move between legs or affects different limbs on different occasions.

Reduced appetite and lethargy

General unwellness often accompanies the joint signs, suggesting systemic involvement.

Later signals

Visible joint swelling

Affected joints may appear enlarged or feel warm compared to normal.

Fever

Elevated body temperature reflecting the inflammatory process.

Pain on joint manipulation

Clear discomfort when affected joints are flexed or extended during examination.

Reluctance to bear weight

More obvious lameness or reluctance to put weight on affected limbs.

Click to read about the biological mechanisms

How this is usually investigated

Diagnosis requires demonstrating joint inflammation whilst excluding infectious causes and identifying any underlying conditions. Joint fluid analysis is central to diagnosis.

Joint fluid analysis (arthrocentesis)

Purpose: To collect fluid from affected joints for laboratory examination
Considerations: Typically shows increased white blood cells (predominantly neutrophils) without evidence of infection. Multiple joints are usually sampled.

Blood tests

Purpose: To assess overall health, check for infection, and evaluate inflammatory markers
Considerations: May show elevated white blood cell counts and inflammatory markers. Also helps screen for underlying conditions.

Radiographs of affected joints

Purpose: To assess joint structures and rule out other causes of joint disease
Considerations: Early IMPA may show minimal changes. Soft tissue swelling and joint effusion may be visible. Chronic cases may show bony changes.

Bacterial culture of joint fluid

Purpose: To exclude infectious (septic) arthritis
Considerations: Essential before starting immunosuppressive treatment, as septic arthritis requires different management.

Testing for underlying conditions

Purpose: To identify secondary causes such as infections or neoplasia
Considerations: May include tick-borne disease testing, chest radiographs, abdominal ultrasound, or other investigations depending on clinical presentation.

Options & trade-offs

Treatment aims to suppress the abnormal immune response whilst addressing any underlying cause. Long-term management is often necessary.

Immunosuppressive doses of corticosteroids

Higher doses of steroids to dampen the immune attack on joints.

Trade-offs: Usually effective initially. Associated with predictable side effects including increased thirst, hunger, and urination. Long-term use requires monitoring for complications.

Steroid-sparing immunosuppressive drugs

Medications such as azathioprine, ciclosporin, or mycophenolate used to reduce steroid requirements.

Trade-offs: May allow steroid dose reduction. Each has specific monitoring requirements. May take weeks to reach full effect.

Treatment of underlying conditions

Addressing any identified triggers such as infections or other diseases.

Trade-offs: Essential for secondary IMPA. Resolution of the underlying cause may allow immunosuppressive treatment to be reduced or stopped.

Pain management

Analgesic medications to provide comfort whilst anti-inflammatory treatment takes effect.

Trade-offs: Improves quality of life during flares. Some pain medications may need to be used cautiously alongside immunosuppressive drugs.

Gradual medication reduction

Slowly tapering immunosuppressive treatment once the condition is controlled.

Trade-offs: Aims to find the minimum effective dose or achieve drug-free remission. Relapse can occur, requiring treatment adjustment.

Common misconceptions

Misconception:

"IMPA is the same as osteoarthritis"

Reality:

These are fundamentally different conditions. IMPA results from immune attack on joints, whilst osteoarthritis develops from wear and tear. They require different treatments.

Misconception:

"Once symptoms improve, treatment can stop immediately"

Reality:

IMPA typically requires gradual treatment tapering over months to minimise relapse risk. Stopping treatment abruptly often leads to recurrence.

Misconception:

"Dogs with IMPA cannot have a good quality of life"

Reality:

With appropriate management, many dogs with IMPA can return to comfortable, active lives. The condition is controllable in most cases, though long-term medication may be needed.

Noting which joints seem affected and whether this changes over time can help characterise the condition. Observing when stiffness is most pronounced, such as after rest versus after activity, provides useful information. Documenting any associated signs such as reduced appetite or apparent fever helps build a complete picture for veterinary evaluation.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS